EN HU

Sebestyén Enikő

Sebestyén Enikő

Publication list

2025
1.
Király, J., Berzi, A., El-Kareh, R., Sebestyén, E., Ujvárosy, D., Emri, M., Bhattoa, H. P., Kappelmayer, J., Miller, K. E., Tóth, G.: Breaking the guidelines: how financial unawareness fuels guideline deviations and inefficient DVT diagnostics.
Diagnosis. 12 (2), 232-240, 2025.
Journal metrics:
Q2 Biochemistry (medical) (2024)
Q2 Clinical Biochemistry (2024)
Q2 Health Policy (2024)
Q2 Medicine (miscellaneous) (2024)
Q2 Public Health, Environmental and Occupational Health (2024)
2.
Sebestyén, E., Csige, D., Antal-Szalmás, P., Horváth, Á., Végh, E., Soós, B., Pethő, Z., Bodnár, N., Hamar, A. B., Bodoki, L., Kacsándi, D., Földesi, R., Kalina, E., Nagy, G., Kerekes, G., Nagy, B. J., Hódosi, K., Szamosi, S., Árkosy, P., Szűcs, G., Szekanecz, Z., Szekanecz, É.: Effects of Tofacitinib Therapy on Circulating Tumour-Associated Antigens and Their Relationship with Clinical, Laboratory and Vascular Parameters in Rheumatoid Arthritis.
Biomolecules. 15 (5), 1-15, (article identifier: 648), 2025.
Journal metrics:
Q1 Biochemistry (2024)
Q2 Molecular Biology (2024)
2023
3.
Sebestyén, E., Major, N., Bodoki, L., Makai, A., Balogh, I., Tóth, G., Orosz, Z., Árkosy, P., Vaskó, A., Hódosi, K., Szekanecz, Z., Szekanecz, É., Hungarian OncoRheumatology Network (HORN) initiative: Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience.
Front Oncol. 13, 1-9, (article identifier: 1252215), 2023.
Journal metrics:
Q2 Cancer Research
Q2 Oncology
DEENK University of Debrecen
© 2012 University of Debrecen